Exenatide for Myocardial Protection During Reperfusion Study
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 198 participants.
Also called NCT01938235
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 198 participants
- Registry
-
NCT01938235
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Unknown status
Technical summary
Registry record NCT01938235. Randomized; quadruple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2017-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Exenatide for Myocardial Protection During Reperfusion Study
- Acronym
- EMPRES
- Condition
- Myocardial Infarction
- Intervention (Drug)
- Exenatide
- Intervention (Drug)
- Placebo
- Lead sponsor
- University Health Network, Toronto
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct01938235- Content hash
d08add24689348fea07dc2348c482b64e0a17ff6dcbee79bbf88a903852a801c